Answers are grounded in this paper and cite their sources.
BACKGROUND: . In 2017, a review of primary hepatic lymphoma (PHL) was done in immunocompetent diffuse large B-cell lymphoma (DLBCL) patients. Yet questions that include treatment choosing or susceptibility of immunoincompetent patients remain disputable. AIM: To investigate the clinical characteristics of patients with PHL. METHODS: We collected PHL cases on PubMed, and extracted demographic and clinicopathological data to perform a systematic analysis. Survival analysis regarding age, lactate dehydrogenase (LDH), liver function abnormality (LFA), and treatment modalities were conducted. The Kaplan-Meier method and Cox regression were used to identify risk factors. Heavy disease burden was observed in deceased patients. A few PHL patients (3.4%) have slightly higher tumor markers. CONCLUSION: PHL patients with elevated LDH and LFA tend to have shorter PFS. Biopsy before treatment in undecided patients with no tumor markers exceeds upper limits has the most essential clinical significance, especially in immunoincompetent patients.
No takes yet. Share an insight, caveat, or question.
Liqun Zou (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: